Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cyclacel Pharmaceuti (CYCC)

Cyclacel Pharmaceuti (CYCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cyclacel Pharmaceuticals Explores Strategic Alternatives to Preserve Cash and Review Potential Transactions

Cyclacel Pharmaceuticals is exploring strategic alternatives to preserve cash, including a potential transaction with investor David Lazar.Quiver AI SummaryCyclacel Pharmaceuticals, Inc. has announced...

CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Closes Transaction for Exercise of Existing Warrants and Issues New Warrants

Cyclacel Pharmaceuticals closed a warrant transaction, generating $2.1 million for working capital and corporate purposes.Quiver AI SummaryCyclacel Pharmaceuticals, Inc. has successfully completed a transaction...

CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces Warrant Exercise Agreement to Raise Approximately $2.1 Million

Cyclacel Pharmaceuticals announces warrant exercise agreement, raising approximately $2.1 million for working capital and corporate purposes.Quiver AI SummaryCyclacel Pharmaceuticals, Inc. announced a...

CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)

Barchart Exclusives

Oracle Stock Is Off Its Highs and Could Be Cheap Here
Oracle Corp. produced higher revenue in Q2 but lower free cash flow and FCF margins. However, ORCL stock is now off its highs and could be undervalued here. Shorting out-of-the-money puts is one way to play it. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar